Expert Interview
Discussing the Recently Published AVANT GUARD Trial Evaluating Pulsed Field Ablation (PFA) as an Initial Therapy for Patients with Persistent Atrial Fibrillation
Ticker(s): BSX, MDT, JNJ, ABTInstitution: UC Health
- Clinical Cardiac Electrophysiology at UC Health
- Has performed over 50 Pulsed Field Abaltion Cases on various systems
- Research Interest in monitoring and diagnosing atrial fibrillation and is a consultant for both Abbott and Medtronic
How are you currently managing patients with persistent atrial fibrillation, and what factors guide your decision to pursue antiarrhythmic drugs versus catheter ablation?
Added By: sara_adminWhat is your interpretation of the AVANT GUARD trial results, particularly regarding the safety and efficacy of pulsed field ablation as an initial therapy?
How do you view PFA compared to traditional thermal ablation technologies (e.g., radiofrequency or cryoablation) in terms of procedural safety, durability, and workflow?
Added By: sara_adminIn which patient populations with persistent AF do you see the greatest potential for first-line ablation using PFA?
Added By: sara_adminWhat barriers (e.g., operator experience, technology availability, reimbursement, or guideline positioning) may impact adoption of PFA as an earlier intervention in clinical practice?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
